Apparently 11 patients treated is sufficient now for developers to go straight into a big Phase III trials

Sounds like Lilly all over again!

Whatever happened to classic drug development?

Obviously the review article I did with Bengt Winblad and Julian Gray didn’t put any one off

>>

http://www.fiercebiotech.com/biotech/early-win-means-phase-3-test-way-for-axovant-s-dementia-drug?utm_medium=nl&utm_source=internal&mrkid=938224&mkt_tok=eyJpIjoiTTJRNE1UQTNNV1prWVdRMCIsInQiOiI3UlpZdEFXMTRldkIySSt3WFQyaitKVGl2YkNENWRNY0V1eUtESjJ5ellmQVVmaURvWXNIbmppYmxjSmZUczA3TkwxejRZMnpvSmlXdTExZk1aYUFIWG1JM1RTT0d4ZGpaR0dGckVybVdMQTgrWDc0VFdBN0ZcLzdrcllkSlh3UjgifQ%3D%3D